Last reviewed · How we verify
NCT06057870
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
trial testing Application on Apple watch in Liver Cirrhosis, Alcoholic in 20 participants. Status unknown.
30 December 2024
Quick facts
| Lead sponsor | Cedars-Sinai Medical Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 10 April 2024 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 July 2025 |
Drugs / interventions tested
- Application on Apple watch
Conditions studied
- Liver Cirrhosis, Alcoholic — all drugs for Liver Cirrhosis, Alcoholic →
Sponsor
Cedars-Sinai Medical Center
Who can join
Eligibility, any sex, with Liver Cirrhosis, Alcoholic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis. This is a feasibility pilot study that will recruit 20 patients. The investigators plan to determine the feasibility of wearable devices to remotely monitor daily activity (e.g., physical activity, sedentary time, sleep), cognitive function, blood pressure, and weight in patients with decompensated cirrhosis, by assessing patient compliance. A patient is considered compliant if they wear the wristwatch at least 10 hours per day and use the Apps, body weight scale, and blood pressure monitor for at least 4 of 7 days
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06057870
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Cirrhosis, Alcoholic
Currently open trials in the same condition.
- NCT06814990 — Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients with Ethyltoxic Liver Cirrhosis and T · NA · recruiting
Other Cedars-Sinai Medical Center trials
Trials by the same sponsor.
- NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
- NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
- NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
- NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
- NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06057870 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
- Last refreshed: 8 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06057870.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing